On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns ...

LLY's stock drops despite Q2 earnings beat, as its oral obesity pill underwhelms with 12.4% weight loss in trial.

Eli Lilly stock tumbled Thursday on an unexpected setback for its obesity franchise, sending shares of its rival flying.

Investing.com -- Viking Therapeutics (NASDAQ: VKTX) stock rose 11% Thursday after Eli Lilly’s (NYSE: LLY) data on its oral ...

Eli Lilly (LLY) stock dips as the company reports Phase 3 trial results for its oral obesity drug orforglipron. Read more ...